What changed in this filing

/stocks — the workspaceLOADING

Item 5. Market for Registrant’s Common Equity

2024-04-11 compared with 2023-03-09 · 15 added, 63 removed, 5 unchanged (94% of the section changed)

2 unchanged sentences

Market Information

Our common stock is traded on Nasdaq under the symbol

As of March 6, 2023, there were approximately 29 holders

of record of our common stock.

This number does not include stockholders who are beneficial owners, but whose shares are held in street

name by brokers and other nominees.

This number of holders of record also does not include stockholders whose shares may be held in trust

by other entities.

Our common stock is traded on Nasdaq under the

symbol “ONCO.”

As of April 5, 2024, there

were approximately 39 holders of record of our common stock.

This number does not include stockholders who are beneficial owners, but

whose shares are held in street name by brokers and other nominees.

This number of holders of record also does not include stockholders

whose shares may be held in trust by other entities.

Recent Sales of Unregistered Securities

There are no transactions

that have not been previously included in a Current Report on Form 8-K, aside from the following:

As discussed above, on

October 9, 2022, the Company and Boustead entered into a Settlement Agreement pursuant to which Boustead agreed to waive certain obligations

of the Company under the Underwriting Agreement that was entered into between the two parties in connection with the Company’s IPO

in February 2022.

Pursuant to this agreement, the Company issued to Boustead 93,466 shares of restricted common stock in exchange for

the cancellation of 111,111 warrants issued to Boustead in connection with the IPO.

In addition, the Company and Boustead Capital also

entered into the Advisory Agreement for which consideration equal to 200,000 shares of restricted common stock, with no vesting provisions,

was issued to Boustead Capital upon execution of the Advisory Agreement.

Dividend Policy

As of the date of this Annual Report on Form 10-K,

we have not paid any cash dividends to stockholders.

The declaration of any future cash dividend will be at the discretion of our board

of directors and will depend upon our earnings, if any, our capital requirements and financial position, the general economic conditions,

and other pertinent conditions.

It is our present intention not to pay any cash dividends in the foreseeable future, but rather to reinvest

earnings, if any, in our business operations.

Issuer Purchases of Equity Securities

On November 10, 2022, the Company’s Board

of Directors approved a share repurchase program to allow for the Company to repurchase up to 5 million shares of common stock, with discretion

to management to make purchases subject to market conditions.

The maximum purchase price is $2.00 per share and there is no expiration

date for this program.

Below is a summary of stock

repurchases for the three months ended December 31, 2022.

See Note 6 of our Notes to Financial Statements for information regarding

our stock repurchase program.

Total Number of Shares

Maximum Number of Shares

Beginning repurchase authority

November 1 – November 30, 2022

Shares repurchased

December 1 - December 31, 2022

Shares repurchased

(1) On November 10, 2022, the Board approved a share repurchase program to allow for the Company

to repurchase up to 5 million shares of the Company’s common stock at a price of $1.00 per share, with discretion to management

to make purchases subject to market conditions.

On November 18, 2022 the Board approved an increase in the price to $2.00 per share.

Initial Public Offering

On February 23, 2022, we completed our initial public

offering, or IPO, in which we issued and sold 2,222,222 shares of our common stock, at a public offering price of $9.00 per share.

received net proceeds of $17.1 million, after deducting underwriting discounts and commissions and other offering costs.

the net proceeds of our IPO to fund our research and development activities, clinical trials and the regulatory review process for our

product candidates, and the remainder for working capital and other general corporate purposes.

The foregoing expected use of net proceeds from

our initial public offering represents our intentions based upon our current plans and business conditions.

However, the nature, amounts

and timing of our actual expenditures may vary significantly depending on numerous factors.

For example, we may also elect to use proceeds

from the initial public offering to acquire complimentary technologies, products or businesses, although we are not a party to any letters

of intent or definitive agreements for any such acquisition.

As a result, our management has and will retain broad discretion over the

allocation of the net proceeds.

We may find it necessary or advisable to use the net proceeds for other purposes, and we will have broad

discretion in the application of net proceeds.

As of the date of this Annual

Report on Form 10-K, we have not paid any cash dividends to stockholders.

The declaration of any future cash dividend will be at the discretion

of our board of directors and will depend upon our earnings, if any, our capital requirements and financial position, the general economic

conditions, and other pertinent conditions.

It is our present intention not to pay any cash dividends in the foreseeable future, but rather

to reinvest earnings, if any, in our business operations.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 5. Market for Registrant’s Common Equity